Original news and analysis on international IP policy
NAIROBI, Kenya -- A dispute between Kenyan researchers and the University of Manchester, United Kingdom, over ownership of a cancer discovered after successful clinical trials in Kenya finally seems headed to courts.
An "Access to Vaccines Index" was released today in the Netherlands that claims to "reveal the first landscape of vaccine company actions to improve immunisation coverage."
By Roya Ghafele, OxFirst - Dieter Ernst’s study is one of the few, if not the only one, to thoroughly examine the role, function and effects of Standard Essential Patents from a developing country’s perspective. As such, the study is a refreshing read, given that the discourse on Standard Essential Patents and the FRAND (fair reasonable and non-discriminatory) regime is pretty much driven from a developed country’s point of view.
Sirena Rubinoff writes: What if there was a crystal ball that could tell you where and when to invest your money? It sounds like science fiction, but engineers at MIT have actually developed a formula that can predict future events in tech development. The formula is based on a combination of big data from patent applications and smart analytics which, when put together, can estimate how fast a technology is advancing.
The World Trade Organization committee on intellectual property rights met this week with some discussion items that departed from past agendas but are becoming more familiar. A discussion on electronic commerce revealed interest from members, despite a slow start on details. And discussions on the United Nations High-Level Panel on Access to Medicines prompted nourished interactions and a wish by some countries to pursue the subject in future sessions.
Public health stakeholders – and just about everyone else – may take notice of a meeting planned for May in the Netherlands, as it could offer the beginning of a new approach to pharmaceutical costs. High drug prices have become a ‘kitchen table’ issue in countries of all economic sizes recently, and the World Health Organization is teaming up with the Dutch government to address it in a new and practical way.
Financing for research and development into so-called neglected diseases – those predominantly affecting lower-income populations – rose recently mainly due to the Ebola outbreak, and private sector contributions represent a bigger share, according to the latest available data from a Gates Foundation-supported database.
Big Pharma wants to develop treatments for rare diseases, with government support. The International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) this week launched a new report describing policy priorities to increase research and development into rare diseases.
Microbial resistance to antibiotics has been rising and the world is now facing the serious possibility of falling back to the days when infectious diseases were hardly treatable. The World Health Organization today published a list of bacteria for which new antibiotics are most urgently needed, to help with the race against time, as the medical world is running out of treatment options.
The lack of access to medical products has spread from being a developing country problem to a global one as prices are now too high even for developed country patients and health systems for some medicines. An event at the Graduate Institute Global Public Health Centre yesterday was an opportunity to explore these issues.